Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Part of paid clinical trials in Los Angeles, California.

Sponsor
University of Nebraska
Study ID
NCT00004112
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • rituximab — BIOLOGICAL
  • CHOP regimen — DRUG
    Cyclophosphamide, vincristine and doxorubicin as a drip into the bloodstream (intravenously) and prednisolone (steroid) as tablets taken with or after food.
  • cyclophosphamide — DRUG
  • doxorubicin hydrochloride — DRUG
  • prednisone — DRUG
  • vincristine sulfate — DRUG

Study Details

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies, such as rituximab, can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. It is not yet known whether combination chemotherapy plus rituximab is more effective than combination chemotherapy alone for non-Hodgkin's lymphoma. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without rituximab in treating patients who have newly diagnosed non-Hodgkin's lymphoma that has not been treated previously.

Key Dates

Start date
Sep 1, 1999
Status verified
Sep 2024
Primary completion
Dec 1, 2000
Completion
Mar 1, 2003

Study Design

Allocation
RANDOMIZED
Primary purpose
TREATMENT

Locations (2)

FacilityCityStateZIPSite coordinators
Jonsson Comprehensive Cancer Center, UCLALos AngelesCalifornia90095-1781-
University of Nebraska Medical CenterOmahaNebraska68198-3330-

Find similar trials in Los Angeles, CA

By research site
Jonsson Comprehensive Cancer Center, UCLA· Los Angeles, CAUniversity of Nebraska Medical Center· Omaha, NE

Related Studies